Table 1.
Baseline characteristics.
| All (n = 23) | Sinus rhythm at follow-up (n = 16) | Atrial fibrillation at follow-up (n = 7) | |
|---|---|---|---|
| Male, n (%) | 14 (61) | 10 (62) | 4 (57) |
| Age (years) | 62 ± 7 | 62 ± 8 | 61 ± 4 |
| Body mass index (kg/m2) | 27 ± 4 | 28 ± 4 | 30 ± 5 |
| Hypertension, n (%) | 12 (52) | 8 (50) | 4 (57) |
| Diabetes mellitus, n (%) | 5 (21) | 3 (19) | 2 (29) |
| Ischemic heart disease, n (%) | 2 (9) | 1 (6) | 1 (14) |
| Stroke, n (%) | 1 (4) | 0 (0) | 1 (14) |
| Heart failure, n (%) | 1 (4) | 0 (0) | 1 (14) |
| Echocardiography | |||
| Normal or slightly impaired (LVEF >45%), n (%) | 22 (96) | 16 (100) | 6 (86) |
| Moderately impaired (LVEF 30%–44%), n (%) | 1 (4) | 0 (0) | 1 (14) |
| Medication (baseline) | |||
| Beta-blockers, n (%) | 17 (83) | 13 (81) | 14 (86) |
| Calcium antagonists, n (%) | 6 (26) | 4 (25) | 2 (29) |
| Digoxin, n (%) | 5 (18) | 4 (25) | 1 (14) |
| ACE inhibitors or ARB, n (%) | 11 (48) | 7 (44) | 4 (57) |
| Diuretics, n (%) | 7 (30) | 4 (25) | 3 (43) |
| Warfarin, n (%) | 23 (100) | 16 (100) | 7 (100) |
| Statins, n (%) | 7 (39) | 3 (19) | 4 (57) |
| Apnea-hypopnea index (AHI), events/h | 24 ± 16 | 23 ± 16 | 28 ± 17 |
| Obstructive AHI, events/h | 18 ± 14 | 18 ± 15 | 18 ± 17 |
| Central AHI, events/h | 6.3 ± 14 | 4.8 ± 12 | 10 ± 17 |
Data are presented as means ± standard deviation for continuous variables, or numbers and percentages for dichotomous variables.
ACE: angiotensin-converting enzyme; AHI: apnea-hypopnea index; ARB: angiotensin II receptor blocker; LVEF: left ventricular ejection fraction.